Hypoxia and muscle maintenance regulation: Implications for chronic respiratory disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 14, Issue 6, 2011, Pages 548-553

  Theije, Chiel De ^a   Costes, Frédéric ^b,c   Langen, Ramon C ^a   Pison, Christophe ^d,e,f,g   Gosker, Harry R ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL NORD   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIV GRENOBLE ALPES   (France)

^f INSERM   (France)

^g European Institute for Systems Biology and Medicine   (France)

Author keywords

atrophy; chronic respiratory failure; hypoxia; metabolism; skeletal muscle

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

AEROBIC METABOLISM; CHRONIC RESPIRATORY FAILURE; HUMAN; HYPOXIA; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE METABOLISM; NONHUMAN; REVIEW; SKELETAL MUSCLE;

ANIMALS; ANOXIA; CHRONIC DISEASE; HUMANS; MODELS, ANIMAL; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MUSCULAR DISEASES; OXIDATIVE STRESS; PHENOTYPE; RESPIRATORY INSUFFICIENCY;

EID: 80054979229     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32834b6e79     Document Type: Review

References (66)

1. Eliason G, Abdel-Halim S, Arvidsson B, et al. Physical performance and muscular characteristics in different stages of COPD. Scand J Med Sci Sports 2008; 19:865-870.
2. Gosker HR, Engelen MPKJ, van Mameren H, et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002; 76:113-119. (Pubitemid 34686556)
3. Gosker HR, Zeegers MP, Wouters EF, Schols AM. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax 2007; 62:944-949. (Pubitemid 350084491)
4. Rabinovich RA, Vilaro J. Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2010; 16:123-133.
5. ScholsAM, Gosker HR. The pathophysiology of cachexia in chronic obstructive pulmonary disease. Curr Opin Support Palliat Care 2009; 3:282-287.
6. Lundby C, Calbet JA, Robach P. The response of human skeletal muscle tissue to hypoxia. Cell Mol Life Sci 2009; 66:3615-3623.
7. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364:656-665.
8. Taylor CT, Cummins EP. The role of NF-kappaB in hypoxia-induced gene expression. Ann N Y Acad Sci 2009; 1177:178-184.
9. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132:344-362.
10. Boyer SJ, Blume FD. Weight loss and changes in body composition at high altitude. J Appl Physiol 1984; 57:1580-1585. (Pubitemid 15216459)
11. Hoppeler H, Kleinert E, Schlegel C, et al. Morphological adaptations of human skeletal muscle to chronic hypoxia. Int J Sports Med 1990; 11:S3-S9. (Pubitemid 20120060)
12. Favier FB, Costes F, Defour A, et al. Downregulation of Akt/mammalian target of rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia. Am J Physiol Regul Integr Comp Physiol 2010; 298:R1659-R1666.
13. Hayot M, Rodriguez J, Vernus B, et al. Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli. Mol Cell Endocrinol 2011; 332:38-47.
14. Ren H, Accili D, Duan C. Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways. Proc Natl Acad Sci USA 2010; 107:5857-5862.
15. Koritzinsky M, Rouschop KM, van den Beucken T, et al. Phosphorylation of eIF2alpha is required for mRNA translation inhibition and survival during moderate hypoxia. Radiother Oncol 2007; 83:353-361. (Pubitemid 46907975)
16. Koumenis C, Naczki C, Koritzinsky M, et al. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2. Mol Cell Biol 2002; 22:7405-7416.
17. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10:307-318.
18. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278:29655-29660. (Pubitemid 36962350)
19. Inoki K, Zhu T, Guan K-L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115:577-590. (Pubitemid 37506046)
20. Liu L, Cash TP, Jones RG, et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006; 21:521-531. (Pubitemid 43228007)
21. Jin H-O, Seo S-K, Woo S-H, et al. Activating transcription factor 4 and CCAAT/enhancer-binding protein-beta negatively regulate the mammalian target of rapamycin via Redd1 expression in response to oxidative and endoplasmic reticulum stress. Free Rad Biol Med 2009; 46:1158-1167.
22. DeYoung MP, Horak P, Sofer A, et al. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 2008; 22:239-251.
23. Bellot G, Garcia-Medina R, Gounon P, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009; 29:2570-2581.
24. Rouschop KMA, Beucken TVD, Dubois L, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. Cancer 2010; 120:127-141.
25. Sandri M. Autophagy in skeletal muscle. FEBS Lett 2010; 584:1411-1416.
26. Cannata DJ, Ireland Z, Dickinson H, et al. Maternal creatine supplementation from mid-pregnancy protects the diaphragm of the newborn spiny mouse from intrapartum hypoxia-induced damage. Pediatr Res 2010; 68:393-398.
27. Razeghi P, Baskin KK, Sharma S, et al. Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. Biochem Biophys Res Commun 2006; 342:361-364. (Pubitemid 43289002)
28. Li H, Malhotra S, Kumar A. Nuclear factor-kappa B signaling in skeletal muscle atrophy. J Mol Med 2008; 86:1113-1126.
29. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403. (Pubitemid 38591410)
30. Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt-and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol 2010; 298:H1565-H1570.
31. Sartori R, Milan G, Patron M, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 2009; 296:C1248-C1257.
32. Trendelenburg AU, Meyer A, Rohner D, et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009; 296:C1258-C1270.
33. Flueck M. Plasticity of the muscle proteome to exercise at altitude. High Alt Med Biol 2009; 10:183-193.
34. Murray AJ. Metabolic adaptation of skeletal muscle to high altitude hypoxia: how new technologies could resolve the controversies. Genome Med 2009; 1:117.
35. Gosker HR, Schols AM. Muscle metabolic modulation by chronic hypoxia. J Proteome Res 2007; 6:3400-3401. (Pubitemid 47522729)
36. Vijayasarathy C, Damle S, Prabu SK, et al. Adaptive changes in the expression of nuclear and mitochondrial encoded subunits of cytochrome c oxidase and the catalytic activity during hypoxia. Eur J Biochem 2003; 270:871-879. (Pubitemid 36315330)
37. Formenti F, Constantin-Teodosiu D, Emmanuel Y, et al. Regulation of human metabolism by hypoxia-inducible factor. Proc Natl Acad Sci USA 2010; 107:12722-12727.
38. Mason SD, Howlett RA, Kim MJ, et al. Loss of skeletal muscle HIF-1alpha results in altered exercise endurance. PLoS Biol 2004; 2:e288.
39. Regnault TR, Zhao L, Chiu JS, et al. Peroxisome proliferator-activated receptor-beta/delta,-gamma agonists and resveratrol modulate hypoxia induced changes in nuclear receptor activators of muscle oxidative metabolism. PPAR Res 2010; 2010:129173.
40. Lunde IG, Anton SL, Bruusgaard JC, et al. Hypoxia inducible factor 1{alpha} links fast-patterned muscle activity and fast muscle phenotype in rats. J Physiol 2011; 589:1443-1454.
41. Mounier R, Pedersen BK, Plomgaard P. Muscle-specific expression of hypoxia-inducible factor in human skeletal muscle. Exp Physiol 2010; 95:899-907.
42. Remels AH, Gosker HR, Schrauwen P, et al. Peroxisome proliferator- activated receptors: a therapeutic target in COPD? Eur Respir J 2008; 31:502-508.
43. Remels AH, Langen RC, Schrauwen P, et al. Regulation of mitochondrial biogenesis during myogenesis. Mol Cell Endocrinol 2010; 315:113-120.
44. Shoag J, Arany Z. Regulation of hypoxia-inducible genes by PGC-1 alpha. Arterioscler Thromb Vasc Biol 2010; 30:662-666.
45. O'Hagan KA, Cocchiglia S, Zhdanov AV, et al. PGC-1alpha is coupled to HIF-1alpha-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells. Proc Natl Acad Sci USA 2009; 106:2188-2193.
46. Remels AH, Gosker HR, Schrauwen P, et al. TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? FASEB J 2010; 24:5052-5062.
47. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD), with and without chronic respiratory failure. Eur Respir J 1990; 3:192-196. (Pubitemid 20066922)
48. Swallow EB, Barreiro E, Gosker H, et al. Quadriceps muscle strength in scoliosis. Eur Respir J 2009; 34:1429-1435.
49. Mainguy V, Maltais F, Saey D, et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 2010; 65:113-117.
50. Remels AH, Schrauwen P, Broekhuizen R, et al. Peroxisome proliferatoractivated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 2007; 30:245-252. (Pubitemid 47194177)
51. Doucet M, Russell AP, Leger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:261-269. (Pubitemid 47195876)
52. Plant PJ, Brooks D, Faughnan M, et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2010; 42:461-471.
53. Crul T, Testelmans D, Spruit MA, et al. Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol Biochem 2010; 25:491-500.
54. Jatta K, Eliason G, Portela-Gomes GM, et al. Overexpression of von Hippel-Lindau protein in skeletal muscles of patients with chronic obstructive pulmonary disease. J Clin Pathol 2009; 62:70-76.
55. Agusti A, Morla M, Sauleda J, et al. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004; 59:483-487. (Pubitemid 38797520)
56. Takabatake N, Nakamura H, Minamihaba O, et al. A novel pathophysiologic phenomenon in cachexic patients with chronic obstructive pulmonary disease: the relationship between the circadian rhythm of circulating leptin and the very low-frequency component of heart rate variability. Am J Respir Crit Care Med 2001; 163:1314-1319. (Pubitemid 32506592)
57. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:1239-1245.
58. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1179-1184. (Pubitemid 30243827)
59. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 2008; 586:4055-4059.
60. Jakobsson P, Jorfeldt L. Long-term oxygen therapy may improve skeletal muscle metabolism in advanced chronic obstructive pulmonary disease patients with chronic hypoxaemia. Respir Med 1995; 89:471-476.
61. Mineo D, Ambrogi V, Lauriola V, et al. Recovery of body composition improves long-term outcomes after lung volume reduction surgery for emphysema. Eur Respir J 2010; 36:408-416.
62. Mineo D, Ambrogi V, Cufari ME, et al. Variations of inflammatory mediators and alpha1-antitrypsin levels after lung volume reduction surgery for emphysema. Am J Respir Crit Care Med 2010; 181:806-814.
63. Evans AB, Al Himyary AJ, Hrovat MI, et al. Abnormal skeletal muscle oxidative capacity after lung transplantation by 31P-MRS. Am J Respir Crit Care Med 1997; 155:615-621. (Pubitemid 27085810)
64. Guerrero K, Wuyam B, Mezin P, et al. Functional coupling of adenine nucleotide translocase and mitochondrial creatine kinase is enhanced after exercise training in lung transplant skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1144-R1154. (Pubitemid 41397065)
65. Wang XN, Williams TJ, McKenna MJ, et al. Skeletal muscle oxidative capacity, fiber type, and metabolites after lung transplantation. Am J Respir Crit Care Med 1999; 160:57-63. (Pubitemid 29326068)
66. Pison CM, Cano NJ, Cherion C, et al. Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial. Thorax 2011. [Epub ahead of print]. http://thorax.bmj.com/content/early/2011/06/23/thx.2010.154922.